Pharma’s ‘Come-to-Jesus Moment’: The Industry Braces for a Pelosi Speakership & Democrats’ Drug Pricing Agenda
October 30, 2018 / Pharma / Drug Pricing
Nancy Pelosi marched into PhRMA’s offices this July with the law on her side. Never mind that the law in question has never been put to use: Pelosi spoke in detailed terms of a federal statute that allows the U.S. government to effectively strip drug companies of exclusive licenses to some blockbuster medicines.
Novo Nordisk Leads Pharma Pack Breaking Into Reputation Institute’s Corporate Responsibility Ranking
October 30, 2018 / Pharma / Johnson & Johnson / Novo Nordisk
Big pharma’s reputation may be on the upswing, at least when it comes to corporate responsibility. Last year only Johnson & Johnson cracked the top 100 in Reputation Institute’s annual measurement of public perceptions. But this year, seven made the cut—and Novo Nordisk vaulted into the top 10 at No. 5.
October 30, 2018 / Eli Elly / Licensing / Pharma
Eli Lilly has entered a global licensing and research alliance with Dicerna Pharmaceuticals to identify, develop and commercialise potential therapies for cardio-metabolic conditions, neurodegeneration and pain. As part of the deal, Lilly will also buy a $100m equity stake in Dicerna Pharmaceuticals.
October 29, 2018 / Pharma / Eli Lilly / Rnai Therapies
For the second time in less than one week, Cambridge, Mass.-based Dicerna Pharmaceutical has forged a licensing agreement for its GalXC RNAi technology platform. This time Dicerna and Eli Lilly have struck an agreement to use the platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.
October 29, 2018 / Technology / Diabetes / Amazon / Cardiovascular
The Seattle tech giant has joined forces with brand consultancy business Arcadia Group to launch Choice, a brand of consumer-use medical devices.
October 26, 2018 / Pharma / Drug Pricing / Trump
The Trump administration’s drug-pricing plan puts the U.S. on a path toward policies like those in Europe, where governments use tight cost controls.
October 26, 2018 / Pharma
Pharma buyers are increasingly looking to acquire platform technologies as opposed to single assets, which coupled with high valuations, has led to a slowdown in deal activity, according to two attorneys speaking at a roundtable by Paul Hastings’ M&A practice.
October 26, 2018 / Biotech / Venture Capital / AI / XtalPi / Drug Discovery
Chinese AI drug discovery startup XtalPi has raised another $46 million this year, in an extension of its venture capital round, to finance expansion of its computerized pharmaceutical research platform.
October 29, 2018 / Biotech / Cancer
Scientists at Georgetown University were studying the role of the naturally occurring protein FGFBP3 in cancer when they made a surprising discovery: It helps regulate metabolism. And when they boosted levels of FGFBP3 in mouse models of obesity, the animals lost more than a third of their fat—despite their genetic predisposition to eat continuously.
October 29, 2018 / Pharma / Pfizer
Pfizer is joining forces with Novartis with a throw it all at the wall and see what sticks approach as they look to combine NASH assets to see if it can beat out liver fat, and get a slice of a potentially multi-billion future market.
October 29, 2018 / Pharma / Pfizer / Novo Nordisk / Sanofi
Novo Nordisk and Sanofi deliver some of the world’s top-selling diabetes drugs, and they also deliver the best online experiences for Type 2 diabetes patients, according to new research. That’s the verdict from DRG Digital, which took a deep dive into the websites, patient support, apps and social profiles of six pharma companies to find out where patients were getting the best user experiences.
October 26, 2018 / Pharma / Brexit
Currently, new drugs are approved in the EU by a mutual recognition procedure (MRP) whereby a single EU country assesses the product and awards a marketing authorisation , which then holds for all EU countries. However, Brexit will shake up this system if no deal is reached between the UK and the EU before the end of March 2019.